How Successful Is Immunotherapy for Breast Cancer?

ByMaxine LipnerPublished on August 18, 2023Medically reviewed byDoru Paul, MDImmunotherapycan boost your body's immune response to cancer cells and hopefully kill the

Updated on: November 20,2023

How Successful Is Immunotherapy for Breast Cancer?

ByMaxine LipnerPublished on August 18, 2023Medically reviewed byDoru Paul, MDImmunotherapycan boost your body's immune response to cancer cells and hopefully kill the

Updated on:November 20,2023

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on: October 11,2023

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on:October 11,2023

Who Gets Laryngeal (Voice Box) Cancer?

Dysplasia means precancerous, which isn’t cancer yet, but it could progressByAnna GiorgiPublished on July 24, 2023Medically reviewed byBenjamin F. Asher, MDLaryngeal cancer, al

Updated on: November 21,2023

Who Gets Laryngeal (Voice Box) Cancer?

Dysplasia means precancerous, which isn’t cancer yet, but it could progressByAnna GiorgiPublished on July 24, 2023Medically reviewed byBenjamin F. Asher, MDLaryngeal cancer, al

Updated on:November 21,2023

Success of Rhabdomyosarcoma Treatment in Children

Including Rarer Types of RMS Disease in AdultsByJaime R. Herndon, MS, MPHPublished on July 03, 2023Medically reviewed byDoru Paul, MDRhabdomyosarcomais a kind ofsar

Updated on: November 21,2023

Success of Rhabdomyosarcoma Treatment in Children

Including Rarer Types of RMS Disease in AdultsByJaime R. Herndon, MS, MPHPublished on July 03, 2023Medically reviewed byDoru Paul, MDRhabdomyosarcomais a kind ofsar

Updated on:November 21,2023

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

Updated on: October 27,2023

SGLT2 Inhibitors in Type 2 Diabetes Linked to Lower Risk of Developing GI Cancers

Damian McNamara, MAVANCOUVER, Canada — Use of sodium glucose cotransporter-2 (SGLT2) inhibitors is associated with a reduced risk of gastrointestinal (GI) cancers among patients withtype 2 diabe

Updated on:October 27,2023

Rheumatoid Arthritis: Blood Tests for Diagnosis

Rheumatoid Arthritis: Blood Tests for DiagnosisByLana BandoimUpdated on August 07, 2023Medically reviewed byDavid Ozeri, MDRheumatoid arthritis(RA) can be difficult to di

Updated on: March 17,2024

Rheumatoid Arthritis: Blood Tests for Diagnosis

Rheumatoid Arthritis: Blood Tests for DiagnosisByLana BandoimUpdated on August 07, 2023Medically reviewed byDavid Ozeri, MDRheumatoid arthritis(RA) can be difficult to di

Updated on:March 17,2024

Why start mammograms at 40? Doctor explains new advice

by Samantha Laine Perfas,Harvard UniversityCredit: Unsplash/CC0 Public DomainWomen should start getting regular mammograms at the age of 40, according toa new recommendationbeing dra

Updated on: January 08,2024

Why start mammograms at 40? Doctor explains new advice

by Samantha Laine Perfas,Harvard UniversityCredit: Unsplash/CC0 Public DomainWomen should start getting regular mammograms at the age of 40, according toa new recommendationbeing dra

Updated on:January 08,2024

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on: October 21,2024

Trial supports radiotherapy and cisplatin remaining as the standard of care for p16+ oropharyngeal cancer

by NRG OncologyCredit: Pixabay/CC0 Public DomainThe NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III portion of the study. The ph

Updated on:October 21,2024

α-KG-dependent glycolysis activation by BCAT1 contributes to EGFR-TKI resistance in NSCLC

Updated on: November 28,2024

α-KG-dependent glycolysis activation by BCAT1 contributes to EGFR-TKI resistance in NSCLC

Updated on:November 28,2024

Skin cancer: More people die from types that aren't melanoma, says surprise new finding

by Sarah Allinson,The ConversationCredit: AI-generated imageIf you mention skin cancer, most people think of melanoma—the deadliest skin cancer. The other ones are pretty benign, right?Not so. W

Updated on: October 31,2023

Skin cancer: More people die from types that aren't melanoma, says surprise new finding

by Sarah Allinson,The ConversationCredit: AI-generated imageIf you mention skin cancer, most people think of melanoma—the deadliest skin cancer. The other ones are pretty benign, right?Not so. W

Updated on:October 31,2023

Silent cancers: Here's what you need to know when there are no obvious symptoms

by Justin Stebbing,The ConversationCredit: Pixabay/CC0 Public DomainThe recent revelations about the Princess of Wales'scancer diagnosishighlight a crucial aspect of cancer detec

Updated on: April 06,2024

Silent cancers: Here's what you need to know when there are no obvious symptoms

by Justin Stebbing,The ConversationCredit: Pixabay/CC0 Public DomainThe recent revelations about the Princess of Wales'scancer diagnosishighlight a crucial aspect of cancer detec

Updated on:April 06,2024

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on: October 12,2023

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on:October 12,2023